The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...

Researchers from Kyushu University have developed an innovative computational method, called ddHodge, that can reconstruct ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

A new computational model of the brain based closely on its biology and physiology has not only learned a simple visual ...

Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced the expansion of its Scientific Advisory ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that Nate Fernhoff, Ph.D., Orca Bio’s co-founder and ...

Nexus Power is building biodegradable batteries from crop waste to power EVs, reduce pollution, and replace lithium-based ...

The world of biology and science never ceases to amaze us. This has been demonstrated by what a group of scientists has ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell ...

The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...